Loading…
CytoMed Therapeutics Limited is projected to decline to $0.9033 by 2027, a -2% move from its current price of $0.9192. GDTC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.8788 | $0.9193 | $0.9616 | +0.01% |
| Aug 6 | $0.8627 | $0.9194 | $0.9798 | +0.02% |
| Aug 7 | $0.8505 | $0.9195 | $0.994 | +0.03% |
| Aug 8 | $0.8404 | $0.9196 | $1.01 | +0.04% |
| Aug 9 | $0.8316 | $0.9197 | $1.02 | +0.05% |
| Aug 10 | $0.8238 | $0.9198 | $1.03 | +0.06% |
| Aug 11 | $0.8166 | $0.9199 | $1.04 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8166 | $0.9199 | $1.04 | +0.08% |
| Week 2 | $0.7779 | $0.9206 | $1.09 | +0.15% |
| Week 3 | $0.7496 | $0.9213 | $1.13 | +0.23% |
| Week 4 | $0.7266 | $0.922 | $1.17 | +0.30% |
| Week 5 | $0.707 | $0.9227 | $1.20 | +0.38% |
| Week 6 | $0.6898 | $0.9234 | $1.24 | +0.45% |
| Week 7 | $0.6743 | $0.9241 | $1.27 | +0.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CytoMed Therapeutics Limited is a clinical stage biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials to improve anti-cancer cytotoxicity.
The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has a research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trials in Singapore; and a Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
CytoMed Therapeutics Limited (GDTC) is currently trading at $0.9894 per share, with a market capitalization of $11.71M and a market rank of 4764.
The near-term technical picture shows a neutral stance with RSI14 at 50, and moving averages at SMA50 $1.06 and SMA200 $1.28, with a defined support at $0.88 and resistance at $1.08.
The 30-day price range spans from $0.737 to $1.33, and the stock carries an annualized volatility of 90%, indicating notable price variability.
The multi-year forecast points to a bullish trajectory beginning around 2030, with 2030 avg $1.29 and max $2.11 (min $0.8516), 2040 avg $2.28 and max $4.61, and 2050 avg $5.53 with a max of $12.65, while ROIs rise from 30.3 in 2030 to 459.3 in 2050.
A major floor 21.3% below — a decisive break under it would weaken the trend.
The nearest floor, 4.3% below — buyers have tended to step in here.
The nearest ceiling, 17.5% above — a clean break opens room to run.
A major ceiling 43.6% above — clearing it would confirm fresh momentum.
Key GDTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GDTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9268 | Sell | $0.9397 | Sell |
| MA 10 | $0.9414 | Sell | $0.947 | Sell |
| MA 20 | $0.9677 | Sell | $0.9678 | Sell |
| MA 50 | $1.05 | Sell | $1.01 | Sell |
| MA 100 | $1.02 | Sell | $1.07 | Sell |
| MA 200 | $1.28 | Sell | $1.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.04 | Neutral |
| Stoch RSI (14) | 67.57 | Neutral |
| CCI (20) | -76.42 | Neutral |
| Williams %R (14) | -64.29 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -8.82 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 35.71 | Neutral |
| TRIX (15) | -0.41 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 46.04 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.94 | Sell |
| ADX (14) | 12.17 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows a NEUTRAL stance with RSI 50.
Price action is currently around the SMA50 ($1.06) and below the SMA200 ($1.28), with nearby support at $0.88 and resistance at $1.08.
The 30-day range spans from $0.737 to $1.33, indicating a relatively tight band around the current price. The stock exhibits high volatility, with annualized volatility at 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.723 | $0.9192 | $1.27 | 0% | Neutral | |
| $0.6782 | $0.9033 | $1.29 | -2% | Neutral | |
| $0.6875 | $0.9626 | $1.46 | +5% | Neutral | |
| $0.6876 | $1.00 | $1.59 | +9% | Neutral | |
| $0.7981 | $1.21 | $1.99 | +32% | Bullish | |
| $0.9757 | $1.53 | $2.60 | +67% | Bullish | |
| $0.9685 | $1.57 | $2.74 | +71% | Bullish | |
| $0.9024 | $1.51 | $2.70 | +65% | Bullish | |
| $0.8137 | $1.41 | $2.57 | +53% | Bullish | |
| $0.8359 | $1.49 | $2.77 | +62% | Bullish | |
| $1.04 | $2.12 | $4.31 | +131% | Bullish | |
| $2.34 | $5.19 | $11.91 | +465% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.723 | $0.9192 | $1.17 | +0.00% |
| September 2026 | $0.8085 | $0.9739 | $1.22 | +5.95% |
| October 2026 | $0.7617 | $0.9283 | $1.18 | -4.69% |
| November 2026 | $0.7502 | $0.9231 | $1.19 | -0.56% |
| December 2026 | $0.7845 | $0.9736 | $1.27 | +5.47% |
Click any year to see its month-by-month GDTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GDTC could reach as high as $1.27, with a base case around $0.9192 and support toward $0.723 — roughly 0% from $0.9192. A consolidation phase looks the most probable path here.
Expect GDTC to range from $0.6782 to $1.29 through 2027. The $0.9033 average target implies a -2% move from current prices. That is -2% versus the projected 2026 average. Price action looks broadly range-bound.
The GDTC price prediction for 2028 points to an average of $0.9626 (low $0.6875, high $1.46) — a potential gain of +5% on today's $0.9192. A consolidation phase looks the most probable path here.
In 2029, GDTC is projected to trade between $0.6876 and $1.59, averaging $1.00 — a potential gain of +9% from today's $0.9192. That is up +4% on the projected 2028 average. Price action looks broadly range-bound.
CytoMed Therapeutics Limited's 2030 outlook centres on $1.21, within a $0.7981 to $1.99 range. That is up +21% on the projected 2029 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GDTC could reach as high as $2.60, with a base case around $1.53 and support toward $0.9757 — roughly +67% from $0.9192. Momentum favours further upside here.
Expect GDTC to range from $0.9685 to $2.74 through 2032. The $1.57 average target implies a +71% move from current prices. That is up +3% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The GDTC price prediction for 2033 points to an average of $1.51 (low $0.9024, high $2.70) — a potential gain of +65% on today's $0.9192. Momentum favours further upside here.
In 2034, GDTC is projected to trade between $0.8137 and $2.57, averaging $1.41 — a potential gain of +53% from today's $0.9192. That is -7% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
CytoMed Therapeutics Limited's 2035 outlook centres on $1.49, within a $0.8359 to $2.77 range. That is up +6% on the projected 2034 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2040, GDTC could reach as high as $4.31, with a base case around $2.12 and support toward $1.04 — roughly +131% from $0.9192. Buyers look set to stay in control over this stretch.
Expect GDTC to range from $2.34 to $11.91 through 2050. The $5.19 average target implies a +465% move from current prices. That is up +145% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GDTC today (≈ 1,087.902524 GDTC) could be worth
$5,648.83
+$4,648.83 (+465%) by 2050 · US Dollar
Based on the average projected GDTC price of $5.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GDTCwould be worth at today's price.
$1,000 invested in GDTC on Jul 31, 2025 (≈ 531.914895 GDTC) would be worth
$488.94
-$511.06 (-51.1%) today · 0.49× · US Dollar
Based on a GDTC entry price of $1.88 vs. today's $0.9192.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.99 | $928.48 | -7.2% |
| 1 month ago | $0.99 | $928.48 | -7.2% |
| 3 months ago | $0.974 | $943.74 | -5.6% |
| 6 months ago | $0.86 | $1,068.84 | +6.9% |
| 1 year ago | $1.88 | $488.94 | -51.1% |
| All time (3.3y) ago | $4 | $229.8 | -77.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GDTC forecast.
Our base-case forecast reaches $1.80 around 2040.
Implied market cap at $1.80: $21.3M
The multi-year forecast depicts a shift from neutral to bullish conditions as time extends, with the 2030 average price at $1.29 and a ROI of 30.3, followed by continued upside in subsequent years.
By 2040, the forecast envisions an average price of $2.28 and a ROI of 130.3, with a max of $4.61. The path again accelerates by 2050, showing an average price of $5.53 and a ROI of 459.3, with a max forecast of $12.65.
These figures illustrate substantial long-term upside but are estimates, not guarantees, and depend on clinical outcomes and market conditions. Upside potential is balanced by near-term uncertainty inherent to early-stage biopharmaceuticals.
Tap a question to reveal the answer.
2030 avg $1.29 with min $0.8516 and max $2.11; ROI 30.3; sentiment BULLISH.
The forecast shows NEUTRAL sentiment in 2026 and 2027, then BULLISH from 2030 onward, with 2050 avg $5.53 and ROI 459.3.
Yes. The 2050 max forecast is $12.65, with 2050 avg $5.53 and ROI 459.3.
2026 avg $0.9894; 2027 avg $0.9661; ROI 0 and -2.4; sentiment NEUTRAL.
Current price $0.9894; Market cap $11.71M; rank 4764.
CytoMed Therapeutics Limited Community Discussion
0Share your CytoMed Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.